Abstract：
Over 50 years have passed since discovering mesenchymal stromal cells (MSCs). Initially, despite gaps in the knowledge of the identity of these cells, their therapeutic aspects were recognized. Consequently, MSCs became candidates for treating a wide range of diseases. However, the therapeutic effects of MSCs are not stable in the long term, and there are inconsistent data on their clinical efficacy. Even though more than 1000 MSC-based clinical trials have been registered, and the safety of MSCbased cell therapies has been proven, data on the clinical efficacy of MSCs have not been enough to warrant FDA approval for clinical treatment and marketing purposes. The available information on MSCs still contains some controversies, perhaps owing to little progress in understanding their in vivo identity. MSCs have been used for therapeutic purposes despite poor knowledge of their in vivo origin or functions. Hence, perhaps we need to go back to the basics of MSCs and spend more time understanding the biology of these cells. An improved understanding of MSCs\' location and function within tissues may improve their therapeutic efficacy and, consequently, their establishment as a cell therapy product.
摘要：
自发现间充质基质细胞（MSC）以来，已经过去了50多年。最初，尽管这些细胞的身份知识存在差距，他们的治疗方面得到了认可。因此,MSC成为治疗多种疾病的候选物。然而,MSCs的治疗效果长期不稳定,且其临床疗效数据不一致。尽管已经注册了1000多个基于MSC的临床试验，基于MSC的细胞疗法的安全性已经得到证明，关于MSCs临床疗效的数据还不足以保证FDA批准用于临床治疗和营销目的.现有关于MSCs的资料仍有一些争议,也许是由于在理解他们的体内身份方面进展甚微。尽管对MSC的体内起源或功能了解不足,但MSC已用于治疗目的。因此，也许我们需要回到MSCs的基础上，花更多的时间了解这些细胞的生物学特性。改善对MSCs在组织内的位置和功能的理解可能会提高其治疗功效，因此,他们作为细胞治疗产品的建立。
